QED Therapeutics
Palo Alto
About QED Therapeutics
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $65.0M
- Last round: Series Unknown (Jan 2018)
- Website: qedtx.com
- Phone: 1-877-280-5655
Industries & Categories
Biotechnology, Health Care, Precision Medicine, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/qed-therapeutics-11622 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.